🇺🇸 VRTX — Vertex Pharmaceuticals Incorporated
Salud CompraPrecio actual
549,04 USD
Máx. histórico
558,88
5 días
Split 2:1 del 24/08/2000
Caída desde máximo
-1,76%
Rango 52 semanas
406,67 – 568,67
Variación hoy
+3,44%
Cierre anterior
530,76
Rango de hoy
527,38 – 550,77
Volumen hoy
1.810.311
Peor caída histórica
-91,77%
02/11/2000 → 11/11/2003
Recuperado en 3885 días
Volatilidad anualizada ⓘ
54,63%
- Nombre completo
- Vertex Pharmaceuticals Incorporated
- Divisa
- USD
- Mercado
- NasdaqGS
- Sector
- Salud
- Industria
- Biotechnology
- Empleados
- 6.400
- PER ⓘ
- 36,82 (puede no estar actualizado)
- Dividend yield
- 0,00% (puede no estar actualizado)
- Precio objetivo analistas
- 578,71 USD (puede no estar actualizado)
- Primera cotización
- 24/07/1991
- Precio actualizado
- hace 12 horas
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMKEVI for treatment of patients with CF 6 years of age and older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 month or older who have CF with ivacaftor. The company also develops CASGEVY for the treatment of SCD and TDT; JOURNAVX for the treatment of acute pain in adults; VX-522, a CFTR mRNA therapeutic designed to treat the underlying cause of CF, which is in Phase 1/2 clinical trial; inaxaplin for the treatment of APOL1-mediated kidney disease, which is in single Phase 2 trial; VX-264 for treating Type 1 Diabetes; VX-670 for the treatment of myotonic dystrophy type 1; and VX-407, a small molecule corrector for the treatment of autosomal dominant polycystic kidney disease. In addition, the company also operates as a clinical-stage pharmaceutical company, that focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company sells its products primarily to specialty pharmacy and distributors, wholesalers, retail pharmacies, hospitals, and clinics. Vertex Pharmaceuticals Incorporated has a strategic collaboration with AbCellera Biologics Inc. to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.
| Fecha | Ratio |
|---|---|
| 24/08/2000 | 2:1 |
| Fecha | Apertura | Máximo | Mínimo | Cierre | Variación | Volatilidad día | Volumen |
|---|---|---|---|---|---|---|---|
| 09/02/2016 | 80,25 | 83,53 | 79,44 | 80,14 | -2,27% | 5,10% | 4.159.500 |
| 08/02/2016 | 85,23 | 85,85 | 79,81 | 82,00 | -5,32% | 7,09% | 4.215.100 |
| 05/02/2016 | 89,78 | 92,23 | 84,54 | 86,61 | -5,57% | 8,57% | 4.571.300 |
| 04/02/2016 | 93,49 | 96,35 | 90,71 | 91,72 | -2,30% | 6,03% | 2.453.000 |
| 03/02/2016 | 91,54 | 93,98 | 86,12 | 93,88 | +3,19% | 8,59% | 3.256.700 |
| 02/02/2016 | 90,59 | 92,68 | 89,43 | 90,98 | -1,53% | 3,59% | 3.142.900 |
| 01/02/2016 | 91,92 | 93,99 | 89,75 | 92,39 | +1,81% | 4,61% | 2.913.200 |
| 29/01/2016 | 92,72 | 94,49 | 90,00 | 90,75 | -2,17% | 4,84% | 3.485.600 |
| 28/01/2016 | 91,00 | 94,09 | 81,98 | 92,76 | +0,28% | 13,31% | 8.088.500 |
| 27/01/2016 | 92,35 | 96,09 | 89,92 | 92,50 | +0,33% | 6,68% | 3.626.000 |
| 26/01/2016 | 92,70 | 93,43 | 90,47 | 92,20 | +0,09% | 3,19% | 2.561.800 |
| 25/01/2016 | 94,24 | 95,17 | 92,01 | 92,12 | -2,73% | 3,35% | 2.665.400 |
| 22/01/2016 | 97,00 | 97,81 | 93,65 | 94,71 | -0,38% | 4,29% | 2.572.900 |
| 21/01/2016 | 97,06 | 98,84 | 94,84 | 95,07 | -1,98% | 4,12% | 2.881.100 |
| 20/01/2016 | 93,33 | 98,58 | 89,97 | 96,99 | +2,11% | 9,23% | 4.088.800 |
| 19/01/2016 | 100,54 | 101,46 | 92,57 | 94,99 | -2,98% | 8,84% | 2.779.800 |
| 15/01/2016 | 98,15 | 100,13 | 95,09 | 97,91 | -3,93% | 5,13% | 3.222.200 |
| 14/01/2016 | 97,44 | 103,95 | 94,68 | 101,91 | +5,75% | 9,51% | 3.688.600 |
| 13/01/2016 | 104,30 | 105,50 | 95,68 | 96,37 | -7,01% | 9,42% | 5.709.200 |
| 12/01/2016 | 104,95 | 108,71 | 98,87 | 103,64 | -0,30% | 9,38% | 3.253.500 |
| 11/01/2016 | 109,88 | 109,94 | 101,49 | 103,95 | -6,11% | 7,69% | 3.230.700 |
| 08/01/2016 | 115,62 | 117,11 | 110,55 | 110,71 | -3,70% | 5,67% | 1.823.000 |
| 07/01/2016 | 119,01 | 119,82 | 113,85 | 114,96 | -5,95% | 5,02% | 2.362.600 |
| 06/01/2016 | 120,80 | 123,17 | 119,51 | 122,23 | -0,99% | 3,03% | 1.692.400 |
| 05/01/2016 | 123,89 | 124,96 | 121,90 | 123,45 | +0,46% | 2,47% | 1.299.900 |
| 04/01/2016 | 123,03 | 123,87 | 121,04 | 122,89 | -2,34% | 2,30% | 2.217.600 |
| 31/12/2015 | 125,55 | 127,60 | 124,91 | 125,83 | -0,45% | 2,14% | 797.300 |
| 30/12/2015 | 127,68 | 127,95 | 125,93 | 126,40 | -1,15% | 1,58% | 658.700 |
| 29/12/2015 | 124,97 | 129,18 | 124,32 | 127,87 | +3,16% | 3,89% | 1.168.600 |
| 28/12/2015 | 123,99 | 124,74 | 122,72 | 123,95 | -0,71% | 1,63% | 677.700 |